Invitation to Aiforia's investor webinar on November 17, 2026
Aiforia Technologies Plc, Press Release, October 28, 2026, at 9:00 a.m. EET
Invitation to Aiforia's investor webinar on November 17, 2026
Aiforia Technologies invites investors, analysts and financial media to an investor webinar on Tuesday, November 17, 2026, from 10:00 to approximately 11:30 a.m. EET. At the event, Aiforia and external speakers from the field will cover the latest developments and future outlook of the digital pathology market.
Agenda:
Opening
Jukka Tapaninen, Chief Executive Officer of Aiforia
Customer case: Journey towards adopting digital workflows and AI in pathology
Professor Angelo Paolo Dei Tos, Dean of the University of Padua School of Medicine and Chair of the Department of Integrated Diagnostics at Azienda Ospedale-Università Padova, Italy
Market update: The global digital pathology market
Katie Gillette Maloney, Partner at DeciBio
Aiforia update and closing remarks
Jukka Tapaninen, Chief Executive Officer of Aiforia
Each presentation will be followed by a Q&A session.
The webinar can be followed live at https://events.inderes.com/aiforia/investor-webinar-2026. The webinar will be held in English, and it will include live captioning as well as AI-generated simultaneous interpretation in Finnish. Participants can ask questions via the chat function of the webinar platform.
The presentation material and a recording of the webinar will be available after the event on Aiforia's website at: https://investors.aiforia.com/en/
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Oyj
+33 61 041 6686
https://investors.aiforia.com/
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com